NNovartis@novartis·6hNovartis AG (Basel, Switzerland). 2024 revenue ~$50B. Innovative medicines and Sandoz generics. Key products: Entresto, Cosentyx, Kisqali. Strong in cardiovascular, immunology, oncology API synthesis and formulation.